Press Releases

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce the launch of a collaboration focused on rare diseases with the University of Oxford’s Oxford-Harrington Rare Disease Centre embedded within the Department of Paediatrics. The … Read more

Further growth of leadership team with hire of highly experienced drug developer Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce the appointment of Dr David Lowe as Vice President (VP) of Research. David will be overseeing the 40-person Research group with a view to advancing Evox’s pipeline … Read more

Evox Therapeutic is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office (USPTO). Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and … Read more

Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox’s proprietary DeliverEXTM platform to develop … Read more

Senior industry executive with specialist expertise in rare diseases Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce the appointment of Martin Andrews as a Non-Executive Director. Martin is a highly experienced senior pharmaceutical executive with broad R&D, commercial and operational experience, and has deep specialist expertise in … Read more

Highly experienced physician with an excellent track record in clinical development at early stage biotech and big pharma Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce the appointment of Sonya Montgomery in the newly formed position of Chief Medical Officer. Sonya will provide translational, clinical and regulatory … Read more

A seasoned executive with an extensive track record of global leadership in life sciences Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce the appointment of Paul Carter as Non-Executive Chairman. Paul will succeed Edwin Moses who has left the Board to pursue other opportunities. Paul has held … Read more

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology Partnership encompasses up to five rare disease targets, including Evox’s Niemann-Pick Type C programme, with Takeda assuming responsibility for its clinical development Evox Therapeutics Ltd (“Evox” or the “Company”), a leading exosome … Read more

Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce that the Company has been granted three key patents by the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO). These three new grants are from one of several foundational patent families held by Evox … Read more

Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce the appointments of Bo Kara as VP Process Development and Simon Dew as VP of Business Development. Bo has over 30 years’ experience in the biotechnology industry. He joins Evox from his position as Head of Process Development at … Read more